Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox

NCT02009384 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
2
Enrollment
OTHER
Sponsor class

Stopped low enrollment r/t requirement of prior treatment with denileukin diftitox

Conditions

Interventions

Sponsor

University of Louisville

Collaborators